Cullen L. Myers

VenatoRx Pharmaceuticals (United States)

Biochemistry, Genetics and Molecular BiologyMedicineEnvironmental ScienceImmunology and Microbiology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 3 papers. Top paper: “A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae”.

A new class of penicillin-binding protein inhibitors to address drug-resistant Neisseria gonorrhoeae

bioRxiv (Cold Spring Harbor Laboratory)(2024)10.1101/2024.12.27.630553

N/A

0DataRank · unranked

1 citations

Allison L. Zulli, Brittany Miller, Lindsay M. Avery, Steven A. Boyd, Cassandra L. Chatwin +25 more

Cefepime–taniborbactam and ceftibuten–ledaborbactam maintain activity against KPC variants that lead to ceftazidime–avibactam resistance

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.01511-24

N/A

0DataRank · unranked

8 citations

Annie Stevenson, Brittany Miller, Denis M. Daigle, Tsuyoshi Uehara, Daniel C. Pevear +1 more

Burkholderia pseudomallei PenI β-lactamase and variants are potently inhibited by taniborbactam

Antimicrobial Agents and Chemotherapy(2025)10.1128/aac.00787-25

N/A

0DataRank · unranked

0 citations

Scott A. Becka, Mitchell Edwards, Cullen L. Myers, Kyoko Uehara, Tsuyoshi Uehara +8 more